Eidos Therapeutics Inc
(NASDAQ : EIDX)

( )
EIDX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.61%93.101.3%$988.29m
BIIBBiogen Inc.
-2.52%224.401.3%$650.41m
AMGNAmgen Inc.
-0.81%178.301.3%$468.17m
GILDGilead Sciences, Inc.
-0.38%62.800.9%$434.85m
ILMNIllumina, Inc.
-2.34%314.523.5%$280.91m
REGNRegeneron Pharmaceuticals, Inc.
-1.07%340.462.6%$279.54m
VRTXVertex Pharmaceuticals Incorporated
-1.59%172.581.9%$238.29m
ALXNAlexion Pharmaceuticals, Inc.
-1.72%130.092.0%$169.34m
EXASExact Sciences Corporation
1.27%95.1325.3%$167.52m
AAgilent Technologies, Inc.
0.30%75.791.6%$145.62m
SRPTSarepta Therapeutics, Inc.
0.06%118.1614.7%$133.09m
ONCESpark Therapeutics, Inc.
0.06%110.6711.2%$117.72m
INCYIncyte Corporation
-2.51%73.522.5%$96.42m
IONSIonis Pharmaceuticals, Inc.
-2.23%73.338.3%$95.85m
BMRNBioMarin Pharmaceutical Inc.
-0.59%85.494.3%$92.14m

Company Profile

Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.